Table 1.

Participant Characteristics

	PD			Controls
	mild (Hoehn & Yahr II)	severe (Hoehn & Yahr III-IV)	total
n	52	52	104	64
Age (years)	66.7 ± 5.5 (54–76)	66.3 ± 6.6 (56–80)	66.5 ± 6.1 (54–80)	65.4 ± 6.0 (53–77)
Height (m)	1.73 ± 0.10	1.72 ± 0.08	1.73 ± 0.09	1.68 ± 0.09
Weight (kg)	82.0 ± 14.5	80.1 ± 14.4	81.0 ± 14.4	75.1 ± 15.9
Male (%)	76.9	65.4	71.2	34.4
Disease Duration (years)	7.2 ± 3.9 (1–16)	10.4 ± 6.8 (2–29)	8.8 ± 5.8 (1–29)
Hoehn & Yahr
OFF	2.0 ± 0.0 (2–2)	3.1 ± 0.3 (3–4)	2.5 ± 0.6 (2–4)
ON	2.1 ± 0.3 (2–3)	2.6 ± 0.6 (2–4)	2.4 ± 0.6 (2–4)
Motor UPDRS
OFF	32.8 ± 10.5 (10–58)	38.8 ± 11.9 (12–63)	35.8 ± 11.6 (10–63)
ON	27.7 ± 12.2 (7–57)	31.8 ± 11.5 (7–56)	29.8 ± 11.9 (7–57)
PIGD
OFF	3.6 ± 1.7 (0–8)	5.8 ± 2.3 (1–11)	4.7 ± 2.3 (0–11)
ON	3.2 ± 2.1 (0–7)	4.4 ± 2.3 (0–12)	3.8 ± 2.3 (0–12)
Dyskinesia OFF/ON (n)	0/15	0/25	0/40
ON	5.8 ± 4.3 (1–12)	6.7 ± 4.7 (1–18)	6.5 ± 4.3 (1–18)
PDQ-39 Mobility	13.4 ± 12.3 (0–45)	26.3 ± 17.2 (0–62.5)	20.1 ± 16.1 (0–62.5)
ABC Scale	85.9 ± 14.3 (42.5–100)	75.2 ± 15.9 (44.4–100)	80.4 ± 15.9 (42.5–100)	95.9 ± 5.9 (70.3–100)
Falls	n=49	n=50	n=99	n=46
0	73.5% (36)	54% (27)	63.6% (63)	82.6% (38)
1	20.4% (10)	14% (7)	17.2% (17)	13.0% (6)
≥2	6.1% (3)	32% (16)	19.2% (19)	4.4% (2)
Levodopa Equivalent Daily	718.9 ± 389.0 (200–2100)	2240.7 ± 5666.5 (75–37560)	1480.1 ± 4068.6 (75–37560)
Dose (mg/day)
Amantadine (n)	15% (8)	19% (10)	17% (18)
Agonist (n)	54% (28)	54% (28)	54% (56)
Anticholinergics (n)	2% (1)	10% (5)	6% (6)
MAO-B inhibitor (n)	12% (6)	17% (9)	14% (15)

mean ± std (range)